Browse the evidence

Peripheral oxytocin (OXT) administration can activate hypothalamic oxytocin neurons and normalize feeding circadian rhythms to counteract obesity, offering a non-invasive therapeutic avenue.

This research suggests oxytocin plays a key role in metabolic health. While direct injection is not a current consumer solution, it highlights the importance of circadian eating patterns and may inform future non-invasive therapies.

Adipose tissue NAPE-PLD is essential for the browning process of white adipose tissue; its deletion impairs cold-induced thermogenesis and reduces the expression of browning markers like Ucp1 and Ppargc1a.

Your fat cells can be stimulated to burn more energy, a process called 'browning.' This study shows that specific signaling molecules in fat are required for this process. When these signals are missing, your body struggles to generate heat and burn fat, even in cold conditions. Maintaining healthy fat tissue signaling may support your body's ability to regulate energy expenditure.

Women with polycystic ovary syndrome (PCOS) exhibit significantly higher carotid artery intima-media thickness (CIMT) compared to controls, indicating accelerated subclinical atherosclerosis.

If you have PCOS, your risk for early arterial stiffening is higher than women without the condition. This is not a diagnosis of heart disease, but a signal to aggressively manage blood pressure, lipids, and insulin resistance through diet and exercise to prevent long-term cardiovascular damage.

Disruption of cardiolipin synthesis in thermogenic fat leads to insulin resistance and reduced metabolic flexibility through a mechanism involving ER stress factor CHOP-10.

This finding highlights that brown fat health is not just about burning calories but also about signaling. Disrupting this signaling (via lack of cardiolipin) can lead to insulin resistance. This suggests that preserving brown fat function through lifestyle factors like cold exposure might help maintain insulin sensitivity.

Dietary protein dilution (reducing protein to 5% of calories) improves glucose homeostasis and insulin sensitivity in both lean and obese models by inducing liver-derived FGF21 via the NUPR1 stress response, independent of UCP1 or total caloric intake.

This research suggests that significantly lowering dietary protein (to ~5% of calories) while keeping total calories constant can trigger a liver stress response (NUPR1/FGF21) that improves insulin sensitivity and glucose control, even in obesity. This works independently of weight loss. However, this is a complex metabolic manipulation observed in mice; it does not mean you should simply stop eating protein, as essential amino acids are required for basic function. The key finding is the *ratio* of protein to other macros, not just protein quantity.

High protein intake stimulates postprandial release of gut hormones PYY and GLP-1, but when meals are matched for volume, calories, and appearance, this hormonal increase does not reduce subsequent ad libitum food intake.

Eating a high-protein meal will spike your satiety hormones (GLP-1 and PYY) more than high-fat or high-carb meals of the same size and calories. However, this hormonal spike does not guarantee you will eat less at your next meal. If you match the volume and calories of your meals, you will likely consume the same amount of energy regardless of the protein content.

Activation of mesolimbic GLP-1 receptors (specifically in the VTA and NAc) reduces food reward and intake by lowering the hedonic value and incentive salience of palatable foods, independent of nausea or general motor suppression.

GLP-1 based therapies (like semaglutide or liraglutide) work partly by reducing the 'reward' or 'craving' for highly palatable foods, not just by signaling fullness. This is achieved through action in the brain's reward centers (VTA/NAc). While current peripheral injections may cause nausea, the mechanism suggests that future targeted therapies could reduce cravings without the sickness, making it easier to stick to dietary goals by lowering the hedonic value of food.

Clofibric acid (1.6g/day) prevents the increase of triglyceride levels in newly diagnosed NIDDM patients but has no additional effect on glucose control, cholesterol, or cardiovascular outcomes compared to placebo.

Clofibric acid at 1.6g/day effectively prevents triglyceride increases in newly diagnosed diabetics but does not improve blood sugar or cholesterol. It should be used selectively for patients with high triglycerides, not as a general diabetes treatment.

Past exposure to violence victimization (adolescent or childhood) exacerbates the negative association between loneliness and sleep quality.

If you have a history of violence or maltreatment, loneliness may hit your sleep harder than it does for others. This is likely due to heightened threat sensitivity. Interventions should address both the social connection and the trauma history, as treating one without the other may be less effective.

The mechanism for higher basal MPS in older women involves lower phosphorylation of eEF2Thr56, which deactivates the inhibition of protein elongation.

This is a basic science finding. It explains that women's muscles are biologically set up to build protein more efficiently at rest due to less inhibition of the protein-building machinery (eEF2).

Obesity, particularly when present in early adulthood or involving significant weight gain, is associated with an increased risk of developing Crohn's Disease, but not Ulcerative Colitis.

Maintaining a healthy weight, especially during adolescence and early adulthood, may lower your risk of developing Crohn's Disease. This study suggests that obesity is a specific risk factor for Crohn's but not Ulcerative Colitis. Focus on healthy lifestyle habits early in life to potentially mitigate this risk.

Insulin resistance is the central pathogenic mechanism linking Metabolic Syndrome and NAFLD, driven by visceral adipose tissue expansion and the resulting release of free fatty acids and adipokines.

Fatty liver is not just about fat in the liver; it is a symptom of insulin resistance caused by visceral fat. Treating the underlying insulin resistance through weight loss and exercise is more effective than targeting liver fat alone.

Cidea promotes lipid storage by inhibiting AMPK stability and activity, thereby suppressing fatty acid oxidation and energy expenditure in brown adipose tissue.

Cidea acts as a brake on your body's ability to burn fat by degrading AMPK, a key enzyme that triggers fat burning. Removing this brake (as seen in knockout mice) allows AMPK to function, leading to higher fat oxidation. This suggests that drugs which inhibit Cidea could potentially boost metabolic rate by restoring AMPK activity.

Endurance exercise significantly increases circulating beta-hydroxybutyrate (BHBA), which acts as a signaling molecule that inhibits histone deacetylases (HDACs) and activates the HCA2 receptor, promoting anti-inflammatory and neuroprotective effects.

Endurance exercise naturally boosts BHBA, which helps protect your brain and reduce inflammation. You don't need to force a ketogenic diet to get these benefits; regular aerobic activity is sufficient to trigger this protective signaling pathway.

Endothelial dysfunction, characterized by impaired nitric oxide (NO) production and increased asymmetric dimethylarginine (ADMA), is an early and independent predictor of cardiovascular events in diabetes, often preceding clinical symptoms.

Your blood vessels' ability to dilate and function properly (endothelial function) is a critical early indicator of heart disease risk, often before plaque builds up. In diabetes, this function is impaired due to low nitric oxide and high ADMA. Managing insulin sensitivity and reducing oxidative stress can help improve endothelial health and reduce CVD risk.

In obese individuals, chronically elevated leptin levels induce leptin resistance through impaired blood-brain barrier transport and central receptor signaling deficits, rendering exogenous leptin therapy ineffective for weight loss.

If you are obese, your body likely already has high levels of leptin, but your brain has stopped listening to it (leptin resistance). Therefore, taking leptin supplements or injections will not help you lose weight. The focus should be on improving metabolic sensitivity rather than adding more hormone.

Leptin regulates energy homeostasis not only by acting as a satiety signal in the arcuate nucleus but also by modulating synaptic plasticity and reward perception in extrahypothalamic areas like the ventral tegmental area and striatum.

Your brain's reward system plays a huge role in how much you eat. Leptin helps dampen the 'high' you get from food. In obesity, this reward-dampening fails, making food more appealing. Understanding this biological reward drive can help reduce self-blame for cravings.

Leptin resistance in obesity is driven by impaired transport of leptin across the blood-brain barrier, largely due to saturation by high endogenous levels and inhibition by hypertriglyceridemia.

High blood triglycerides can block leptin from reaching the brain. Managing blood fats may help improve leptin sensitivity.

In euthyroid middle-aged adults, higher free T3 levels and a higher FT3-to-FT4 ratio are positively associated with unfavorable metabolic profiles (higher BMI, waist circumference, triglycerides, blood pressure, fasting glucose, and lower HDL) and increased cardiovascular risk markers (IL-6, hs-CRP, pulse wave velocity).

If you are in the middle-aged range and have metabolic issues (high blood pressure, high triglycerides, central obesity) despite having 'normal' thyroid labs, the ratio of your Free T3 to Free T4 might be a contributing factor. A higher ratio (driven by higher T3 or lower T4) is linked to worse metabolic markers. This suggests that 'normal' TSH doesn't guarantee optimal metabolic health, and the internal conversion of T4 to T3 matters.

Suprapharmacologic doses of anabolic-androgenic steroids (AAS) increase muscle mass and strength in eugonadal men, whereas physiologic doses do not.

If you are a natural, eugonadal male, standard training and nutrition will not trigger the anabolic effects of steroids. The literature indicates that only doses far exceeding physiological levels (10-100x normal) produce significant muscle and strength gains in healthy men. Physiologic replacement doses have no additive benefit over training alone.

In humans, circulating FGF21 exhibits a circadian rhythm with a nocturnal rise peaking in the early morning, and this pattern is driven by oscillations in free fatty acids (FFAs) which stimulate hepatic FGF21 expression via PPARα activation.

This paper establishes that FGF21, a hormone regulating energy metabolism, rises naturally at night in humans, driven by free fatty acids. For obese individuals, this natural nocturnal rise is blunted. While this paper does not prescribe a specific intervention, it suggests that maintaining healthy fatty acid levels (via diet/exercise) may support this natural circadian rhythm, which is disrupted in obesity.

Expression of the Ink4a/Arf locus (p16INK4a and Arf) serves as a robust biomarker of mammalian aging, with expression levels increasing significantly across multiple tissues as organisms age.

This research identifies p16INK4a and Arf as key molecular markers that increase with age in various tissues. While not yet a standard clinical test for everyone, these markers may eventually help predict disease risk and tissue regenerative capacity, offering a way to measure 'biological age' rather than just chronological age.

Ets-1 expression strongly correlates with p16INK4a expression with aging, suggesting Ets-1 is a principal determinant of p16INK4a expression in vivo.

The transcription factor Ets-1 is strongly linked to the increase of p16INK4a during aging. This suggests that stress signals activating Ets-1 may drive the expression of aging-related genes in tissues.

Bariatric surgery is the most effective treatment for both obesity and T2DM, offering benefits beyond weight loss by recovering islet function and normalizing gut hormones.

For severe obesity and T2DM, bariatric surgery is currently the most effective treatment, working by restoring gut hormones (GLP-1, PYY) and beta-cell function, not just by reducing stomach size. It should be considered when lifestyle changes fail, despite surgical risks.